Merrimack Pharmaceuticals, Inc. (MACK)
|Net Income (ttm)||-3.97M|
|Trading Day||June 11|
|Day's Range||6.37 - 6.48|
|52-Week Range||3.07 - 9.45|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results
Merrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially Assumed
Merrimack Pharmaceuticals - A Better Way To Invest In Biotechnology
Merrimack Pharmaceuticals is a special-situations investment.
Merrimack Pharmaceuticals Inc. has announced that it will be discontinuing one of its cancer drugs, as well as conducting layoffs.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
|IPO Date |
Mar 29, 2012
|Stock Exchange |
|Ticker Symbol |
The average 12-month stock price forecast for MACK is 4.00, which is a decrease of -37.79% from the latest price.